Latest filing published 20 Nov 2024 for Syros Pharmaceuticals, Inc., €2,262.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
David Roth, listed as senior executive, appears in our data through filings on Syros Pharmaceuticals, Inc. shares, published by SEC (Form 4). In total, 17 filings cover trades dated from 12 February 2019 to 18 November 2024.
No open-market purchase appears, only 6 sales worth €129k. The rest of the record consists of 6 share grants and 5 option exercises. 2024 to date brings no purchases and 3 sales.
The latest filing, published on 20 November 2024, reports an open-market sale of €2,262 in Syros Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations